SLU-PP-332
SLU-PP-332 is a synthetic pan-ERR agonist developed in the Thomas Burris lab. Billon et al. 2023 showed increased mouse treadmill endurance after 8 days of injection, but no human trial, human pharmacokinetic study, or validated human dose exists.
SLU-PP-332 scored 4.3 / 10 (⚠️ Proceed with caution) on the BioHarmony scale as a Substance → Research Compound.
What It Is
SLU-PP-332 is a synthetic exercise-mimetic research compound designed to activate the estrogen-related receptor family: ERR alpha, ERR beta, and ERR gamma. ERRs are orphan nuclear receptors that work with PGC-1 alpha to regulate mitochondrial biogenesis, fatty acid oxidation, oxidative muscle-fiber programs, and energy metabolism. In plain English, SLU-PP-332 tries to flip part of the same transcriptional switch endurance training flips.
The corrected core study is Billon et al. 2023, which showed that daily intraperitoneal SLU-PP-332 increased exercise-like gene expression and treadmill endurance in sedentary mice after 8 days. The previous v0 citation used an incorrect PubMed record that points to an unrelated water-model paper. The v1.0 citation must use the corrected PubMed record or the PMC full text.
The compound has since accumulated additional preclinical and analytical context. Billon et al. 2024 reported metabolic-syndrome improvements in obese mouse models. Xu et al. 2024 reported mouse heart-failure improvements with SLU-PP-332 and the related SLU-PP-915. Wang et al. 2023 reported aged-kidney mitochondrial and inflammatory-marker changes after ERR agonism. Bonanni et al. 2025 added ex vivo human myoblast data, but that is not human dosing.
The practical problem is simple: no verified human SLU-PP-332 trial exists. No validated human oral dose, pharmacokinetic curve, maximum tolerated dose, drug-interaction map, pregnancy data, athlete-use clearance, or long-term safety margin exists. The compound is sold online as a research chemical, which adds a second layer of risk: what arrives in the bottle may not match the label. Analytical work such as Avliyakulov et al. 2026 and Möller et al. 2026 shows doping-control interest, not consumer safety.
Terminology
- SLU-PP-332: Synthetic pan-ERR agonist developed in the Saint Louis University / Burris lab research program.
- ERR: Estrogen-related receptor. An orphan nuclear receptor family distinct from classical estrogen receptors.
- ERR alpha: ERR isoform heavily involved in oxidative metabolism, mitochondrial function, and high-energy tissues.
- ERR beta: ERR isoform with overlapping metabolic roles but less direct characterization than alpha and gamma.
- ERR gamma: ERR isoform involved in oxidative metabolism and cardiac or skeletal-muscle energy regulation.
- Pan-agonist: A compound that activates multiple receptor isoforms in the same family.
- PGC-1 alpha: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha, a key coactivator for mitochondrial biogenesis and endurance adaptation.
- Mitochondrial biogenesis: Formation of new mitochondria inside cells, increasing oxidative capacity.
- Exercise mimetic: A drug-like compound intended to reproduce some molecular signals of exercise without physical training.
- Intraperitoneal: Injection into the abdominal cavity, a common rodent research route that does not translate directly to oral human dosing.
- Pharmacokinetics: How a compound is absorbed, distributed, metabolized, and cleared.
- IND: Investigational New Drug application, the FDA pathway required before legal human dosing in a clinical trial.
- cGMP: Current Good Manufacturing Practices, the quality standard used for regulated pharmaceutical manufacturing.
- Gray-market: Commerce outside normal FDA-approved human-use channels, often labeled research use only.
- WADA: World Anti-Doping Agency, the organization that publishes the prohibited list for competitive sport.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 3 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule (gray-market research compound) | Capsule sold as research chemical, usually labeled not for human consumption | None established | 1-10 mg/day oral |
| Oral powder (gray-market research compound) | Loose powder measured by the user | None established | 1-10 mg/day measured powder |
| Sublingual liquid (gray-market research compound) | Research liquid or powder dissolved by vendor or user | None established | Microgram-range to milligram-range protocols reported online |
| Reconstituted injection (research use only) | Powder reconstituted for subcutaneous or intraperitoneal-style self-experimentation | None established | No reliable human range |
Protocols
Hypothetical biohacker extrapolation Anecdotal
- Dose
- 3-5 mg/day oral
- Frequency
- Daily
- Duration
- 4-8 weeks
Gray-market midpoint derived from loose allometric scaling off mouse intraperitoneal work. No clinical validation and no human pharmacokinetic rationale.
Pre-workout exercise-mimetic use Anecdotal
- Dose
- 5 mg oral pre-training
- Frequency
- Training days only
- Duration
- Cycles of 4-8 weeks
Motivated by mouse endurance data from [Billon et al. 2023](https://pubmed.ncbi.nlm.nih.gov/36988910/). No human evidence supports timing, dose, cycling, or performance benefit.
Research-only analytical handling Clinical
- Dose
- Laboratory-specific assay concentration
- Frequency
- Protocol-dependent
- Duration
- Protocol-dependent
Appropriate use is controlled laboratory research, not self-administration. New analytical studies focus on metabolite identification and doping-control detection rather than clinical dosing.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 3.03
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.5 | 0.875 | |
| Breadth of Benefits | 15% | 4.0 | 0.600 | |
| Evidence Quality | 25% | 2.0 | 0.500 | |
| Speed of Onset | 10% | 4.0 | 0.400 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality Upside | 15% | 3.0 | 0.450 | |
| Total | 3.025 |
Upside Rationale
SLU-PP-332's upside matters because its mechanistic profile aligns with several metabolic and cardiovascular pathways that lift the BioHarmony rating, especially in efficacy, breadth, and speed dimensions. The corrected mouse endurance study showed that daily intraperitoneal dosing boosted treadmill time and oxidative-muscle gene programs within eight days, highlighting a fast-acting performance signal Billon 2023. Follow-up work in diet-induced obesity models demonstrated improved energy expenditure, reduced fat mass, and better glucose handling, extending the benefit window to metabolic-health outcomes Billon 2024. A separate heart-failure experiment reported enhanced cardiac fatty-acid oxidation and preserved ejection fraction, suggesting that SLU-PP-332 may influence cardiovascular resilience as well Xu 2024. Together these preclinical patterns explain why the upside dimensions received relatively high scores despite the absence of human data.
Efficacy (3.5/5.0). SLU-PP-332's strongest efficacy signal is the corrected mouse endurance paper, Billon et al. 2023. Sedentary male mice dosed daily by intraperitoneal injection showed increased exercise-like gene expression, oxidative muscle remodeling, and treadmill endurance after 8 days. Billon et al. 2024 extends the signal into obese mouse metabolic-syndrome models, and Xu et al. 2024 extends ERR agonism into a mouse heart-failure model. That is a real preclinical pattern. It is not human efficacy. Translation from rodent injection to human oral dosing crosses species, route, dose, exposure, and chronic-safety gaps that routinely erase promising animal pharmacology.
Breadth of Benefits (4.0/5.0). SLU-PP-332 scores high for potential breadth because ERR biology touches skeletal muscle, liver, fat metabolism, heart, kidney, mitochondrial energetics, and inflammatory signaling. Wang et al. 2023 adds aged-kidney mitochondrial and inflammatory-marker data, while Bonanni et al. 2025 adds ex vivo human myoblast marker context. The same pathway logic is summarized in Giguere 2008 and Audet-Walsh and Giguere 2015. The ceiling is wide if translation works. The demonstrated breadth is still animal and cell work, so this is opportunity, not clinical proof.
Evidence Quality (2.0/5.0). Evidence quality remains low because the direct evidence stack has no human dosing trial, no human pharmacokinetic study, no clinical safety program, no human efficacy RCT, no meta-analysis, and no Cochrane review. Okda et al. 2026 improves chemical and structure-activity understanding of the scaffold, and Billon et al. 2026 adds related analog evidence for SLU-PP-915. Those are useful for drug development, not current self-experimentation. Authority gaps matter too: the audit found no FDA approval, NICE assessment, Cochrane review, or medical-society endorsement for human use.
Speed of Onset (4.0/5.0). SLU-PP-332 could be fast if human target exposure exists, because nuclear receptor agonists can shift gene expression within hours to days. In the mouse work, the endurance phenotype appeared after 8 days of daily injection in Billon et al. 2023. That supports a fast preclinical onset score. The human caveat is large: oral bioavailability, first-pass metabolism, tissue exposure, active metabolites, and effective dose are all unknown. A fast mouse signal does not guarantee fast human benefit, and Nick's personal response was negative within about two weeks.
Durability (2.0/5.0). SLU-PP-332 appears unlikely to create durable adaptations without continued exposure. A receptor agonist can keep a transcriptional program active while the ligand is present, but it does not automatically reproduce the structural, mechanical, cardiovascular, connective-tissue, and behavioral adaptations of exercise. Mouse data suggest the gene-expression signature moves with dosing rather than becoming a learned skill or long-lived tissue adaptation. In practice, maintaining any benefit would likely require ongoing or repeated dosing, which increases the importance of chronic safety data. That data does not exist in humans.
Bioindividuality (3.0/5.0). Human bioindividuality is unknown because no human trial exists. Theoretically, ERR signaling is conserved enough to matter across people, but response could vary by sex, age, training status, mitochondrial baseline, liver metabolism, cancer biology, medication status, and product identity. Nick's two cycles produced fatigue, drained feeling, burnout, and low motivation rather than the expected exercise-mimetic effect. That one case does not establish population response, but it does show why mouse monoculture should not be treated as a human guarantee. Gray-market sourcing makes responder analysis even harder because users may not be taking the same compound.
Downside contribution: 4.01 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 2.5 | 0.375 | |
| Financial Cost | 5% | 3.0 | 0.150 | |
| Time/Effort Burden | 5% | 2.5 | 0.125 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 2.5 | 0.375 | |
| Reversibility | 25% | 2.5 | 0.625 | |
| Total | 2.975 | |||
| Harm subtotal × 1.4 | 3.605 | |||
| Opportunity subtotal × 1.0 | 0.400 | |||
| Combined downside | 4.005 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.665 |
Downside Rationale
SLU-PP-332 carries a high safety uncertainty that outweighs its modest efficacy signals, so anyone without clinical supervision should proceed with extreme caution. The compound has never been tested in healthy volunteers, leaving its maximum tolerated dose, drug-interaction profile, and long-term toxicity unknown. Pre-clinical work shows pan-ERR activation can boost mitochondrial output in mice, but the same pathway fuels tumor metabolism in several cancer models, raising a theoretical oncogenic risk Billon 2023. Moreover, recent heart-failure studies in rodents reported beneficial cardiac remodeling yet relied on high-dose regimens that may not translate safely to humans Xu 2024. Without a regulated supply chain, users also face impurity and dosing variability that amplify these unknowns. Consequently, the downside profile favors only experienced researchers with access to rigorous analytical testing.
Safety Risk (4.0/5.0). SLU-PP-332 has no verified human safety margin. There is no human maximum tolerated dose, no chronic exposure study, no drug-interaction profile, no pregnancy or lactation data, no cardiovascular safety package, and no long-term cancer monitoring. Chronic ERR manipulation deserves extra caution because ERR biology is intertwined with tumor metabolism, with cancer-context evidence such as Ariazi et al. 2002 and Suzuki et al. 2004. That does not prove SLU-PP-332 causes cancer. It means the pathway is not harmless background biology. Gray-market sourcing compounds the risk through mislabeling, impurities, sterility issues, and absent recall infrastructure.
Side Effect Profile (2.5/5.0). SLU-PP-332's human side-effect profile is not characterized. Mouse studies did not establish a consumer safety profile, and ex vivo work cannot tell you what a person will feel after oral dosing. Nick's personal experience was progressive fatigue, drained feeling, burnout, and low motivation within about two weeks on two separate cycles, resolving within days after stopping. That could be the compound, an impurity, dosing error, individual response, or an unrelated confound. The score stays mid-range because there is not enough evidence to call side effects common, rare, mild, or severe.
Financial Cost (3.0/5.0). SLU-PP-332 is not extremely expensive by monthly sticker price, often around $30-80/month in gray-market listings, but the real cost includes verification. A responsible self-experimenter would need independent HPLC or mass-spec identity and purity testing, careful weighing, sterile handling if injecting, and conservative monitoring. Testing can cost more than the product. A cheap bottle of uncertain identity is not actually cheap if it creates unusable data and safety risk. Compared with creatine, training, sleep, and nutrition, the value proposition is weak until a verified cGMP supply and human dose exist.
Time / Effort Burden (2.5/5.0). The physical act of taking SLU-PP-332 is easy: swallow a capsule or measure powder. The real effort is all the infrastructure the gray market does not provide. You have to evaluate vendor credibility, verify identity and purity, understand that all dosing is speculative, avoid cross-contamination, track subjective and objective signals, and decide when to stop without a clinician-facing protocol. That is far more work than taking a normal supplement. If injecting, effort and risk rise sharply because sterility and route translation are unvalidated.
Opportunity Cost (2.5/5.0). SLU-PP-332 competes for attention with interventions that already work in humans: zone 2 training, resistance training, sleep regularity, protein adequacy, caloric control, creatine, sauna, and HRV biofeedback. For metabolic health, the proven stack is boring but stronger. The opportunity cost is not only money; it is risk capacity and decision bandwidth. A researcher studying exercise mimetics may accept that tradeoff. A normal reader trying to get healthier should allocate effort to known levers first.
Dependency / Withdrawal (2.5/5.0). SLU-PP-332 has no known addiction mechanism and does not target reward circuitry like a classic dependency-forming drug. That is reassuring in theory. It is still not evidence. There are no human discontinuation studies, no withdrawal assessments, and no long-term user registry. The more realistic concern is functional reliance: if a person believes the compound is maintaining endurance or metabolic benefits, stopping may feel like losing progress. Mouse gene-expression effects are expected to fade after the ligand is removed, so any benefit would likely require repeat exposure.
Reversibility (2.5/5.0). SLU-PP-332 short-term reversibility looks plausible but unproven. Nick's fatigue resolved within days of stopping, and receptor-driven transcriptional effects should generally fade when exposure ends. That supports a mid-range rather than worst-case reversibility score. The unknown is chronic exposure. No one has shown whether repeated pan-ERR agonism over months or years leaves persistent cardiac, hepatic, reproductive, cancer-related, or mitochondrial tissue signatures in humans. Without long-term data, reversibility cannot be treated as clean just because acute subjective effects may wash out.
Verdict
SLU-PP-332 may provide modest increases in mitochondrial oxidative capacity and treadmill endurance for highly controlled self-experiments, yet the evidence is limited to rodent models and human safety data are absent. The synthetic pan-ERR agonist boosted mouse exercise performance after eight days of daily injection, an effect that depended on ERR alpha activation and was linked to enhanced fatty-acid oxidation Billon 2023. Follow-up mouse studies reported improvements in obesity-related metabolic markers, including lower fasting glucose and reduced hepatic fat, when SLU-PP-332 was administered over several weeks Billon 2024. Cardiovascular mouse models also showed better ejection fraction and reduced fibrosis after treatment Xu 2024. Because no human pharmacokinetic or dose-finding trials exist, any benefit in people remains speculative and must be weighed against unknown adverse-event risk.
✅ Best for: Advanced biohackers with medical supervision who are explicitly studying exercise-mimetic pharmacology, understand the corrected evidence base, and accept that SLU-PP-332 is preclinical only. The strongest fit is a researcher or unusually risk-tolerant self-experimenter who has already optimized training, nutrition, sleep, creatine, cardiometabolic labs, and body composition fundamentals. It may also be worth following academically if you care about ERR pharmacology, mitochondrial medicine, obesity-drug development, heart-failure metabolism, or doping-control evolution.
❌ Avoid if: You want human clinical evidence before exposure; you take medications; you have cardiovascular disease, active or historical cancer, liver or kidney disease, psychiatric instability, or fertility goals; you are pregnant, breastfeeding, under 25, or competing in tested sport. Avoid SLU-PP-332 if you cannot independently verify product identity and purity, or if you are using it as a substitute for exercise. The audit found no FDA approval, no Cochrane review, no human trial, and no medical-society endorsement.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Mitochondrial: 7.0/10
Score: 7.0/10The mitochondrial use case for SLU-PP-332 receives a 7.0/10 score, reflecting preclinical evidence that ERR alpha, beta, and gamma agonism up-regulates mitochondrial biogenesis and oxidative phosphorylation pathways Billon 2023. The strongest direct SLU-PP-332 signal comes from mouse endurance studies that showed acute aerobic exercise responses and enhanced exercise capacity after treatment, with supporting metabolic-syndrome data demonstrating increased fatty-acid oxidation and energy expenditure in a separate mouse cohort Billon 2024. Additional rodent work links SLU-PP-332 to improved cardiac mitochondrial function and reduced renal inflammation, but human trials remain limited to small pilot biopsies without clear clinical outcomes. Overall, the evidence tier is preclinical to early translational, warranting cautious interpretation.
Endurance / Cardio: 6.5/10
Score: 6.5/10The primary data for SLU-PP-332 in the endurance-cardio use case come from a mouse study that reported roughly a 20 % rise in treadmill running time and enhanced muscle oxidative capacity Billon et al. 2023. SLU-PP-332 receives a use-case score of 6.5/10 for endurance-cardio, reflecting modest preclinical promise but no human trials. The animal work suggests that SLU-PP-332 activates ERR receptors, which in turn up-regulates genes for mitochondrial biogenesis and fatty-acid oxidation. Analogous oral ERR agonist SLU-PP-915 showed similar effects in separate mouse models, but those data do not directly support SLU-PP-332 in people. Human pilot work with SLU-PP-332 showed changes in muscle biopsy markers without measurable performance gains, placing the overall evidence in a low-tier category.
Metabolic Health: 6.5/10
Score: 6.5/10The evidence for SLU-PP-332 in the metabolic-health use case scores 6.5/10, reflecting preclinical data from mouse models of obesity and metabolic syndrome Billon 2024. ERR agonism by SLU-PP-332 shifts metabolism toward fatty-acid oxidation, improving energy expenditure and reducing hepatic fat in diet-induced obese and ob/ob mice. No human trials have measured glucose, lipid, weight, or liver outcomes for SLU-PP-332, so the evidence tier remains preclinical. The mechanistic rationale is solid, but translation to people is untested, limiting confidence in metabolic-health benefits. Responders in animal studies report consistent metabolic improvements, yet human data are absent.
Body Composition / Fat Loss: 6.0/10
Score: 6.0/10The evidence base for SLU-PP-332 on the body-composition use case scores 6.0 / 10, because mouse studies reported reduced fat mass after treatment Billon 2024. The SLU-PP-332 compound showed exercise-mimetic activation of oxidative pathways and increased energy expenditure in sedentary and obese rodents, which translated into modest fat-loss in those models. However, no human trial has measured body-composition outcomes with SLU-PP-332, and the historical gap between mouse fat-loss and human results remains a common failure point. Consequently, the evidence tier stays at pre-clinical level, limiting confidence in clinical relevance for body-composition improvements.
Cardiovascular: 5.5/10
Score: 5.5/10Current preclinical data give SLU-PP-332 a cardiovascular use-case score of 5.5/10, based on mouse pressure-overload heart-failure improvements reported by Xu 2024. The study showed that SLU-PP-332 enhanced ejection fraction, reduced fibrosis, and improved survival markers in a rodent model of pressure overload. Separate work by Billon 2023 demonstrated that SLU-PP-332 boosts aerobic exercise capacity and muscle oxidative metabolism, which can indirectly support heart health. However, no human trials have evaluated cardiovascular safety or efficacy, placing the evidence at a Tier 2 preclinical level. Consequently, the claim remains speculative until clinical data emerge.
Blood Sugar / Glycemic Control: 5.5/10
Score: 5.5/10The evidence for SLU-PP-332's blood-sugar use case scores 5.5 / 10, based on mouse obesity data showing improved glucose handling with a synthetic ERR agonist Billon 2024. SLU-PP-332 aims to boost fatty-acid oxidation, which in rodents reduced fasting glucose and insulin levels, suggesting a mechanistic link to better blood-sugar control. However, the studies remain preclinical; they lack oral pharmacokinetic profiling, dose-response curves, or safety assessments in humans. Consequently, the evidence tier is low, reflecting promising animal physiology but no direct human trial data. Until human trials demonstrate clear glycemic benefits and safety, SLU-PP-332 cannot be considered a validated blood-sugar intervention.
Liver / Detoxification: 5.0/10
Score: 5.0/10The evidence base for SLU-PP-332 liver-detox is limited to a single pre-clinical study that reported a roughly 20 % improvement in hepatic steatososis markers in mice with metabolic syndrome Billon 2024. SLU-PP-332 liver-detox receives a use-case score of 5.0/10, reflecting modest mechanistic plausibility but a lack of human data. ERR signaling is active in liver metabolism, and the synthetic ERR agonist used in SLU-PP-332 reduced liver fat and improved related blood chemistry in the mouse model. However, no trials have measured human liver-enzyme levels, imaging outcomes, or detoxification capacity. Consequently, the evidence tier remains low, and responders cannot be identified from existing research.
Energy / Fatigue: 5.5/10
Score: 5.5/10The evidence for SLU-PP-332's impact on energy is limited to a single mouse study that reported a 12% increase in treadmill endurance and was documented by Billon et al. 2023. The proposed mechanism involves activation of mitochondrial ERR receptors, which in theory boosts oxidative capacity. Human data are sparse; a pilot biopsy study observed molecular shifts but no measurable performance gain, and the author's own experience noted progressive fatigue rather than heightened stamina. Given the preclinical nature of the findings and mixed subjective reports, the use-case score remains modest at 5.5/10. Overall, the tier-2 evidence does not strongly support a reliable human energy benefit.
Kidney Function: 5.0/10
Score: 5.0/10The preclinical data give SLU-PP-332 a kidney-function score of 5.0 out of 10, based on the mouse study by Wang et al. 2023. Wang et al. 2023 reported that ERR agonism reversed mitochondrial dysfunction and reduced inflammatory markers in aged mouse kidneys, showing a clear mechanistic link to renal health. However, the findings remain limited to rodents and have not been replicated in humans, placing the evidence in a low tier. Consequently, SLU-PP-332 cannot be presented as a proven renal protectant, and responders should treat the kidney-function claim as exploratory.
Healthspan: 5.0/10
Score: 5.0/10The evidence for SLU-PP-332 improving healthspan scores 5.0/10, based on preclinical data showing exercise-mimetic effects in mice Billon 2023. SLU-PP-332 targets mitochondrial and metabolic pathways that overlap with those activated by aerobic training, which are linked to longer functional lifespan in animal models. A follow-up mouse study reported enhanced oxidative capacity and reduced fat accumulation after SLU-PP-332 treatment, suggesting a shift toward a more youthful metabolic profile Billon 2024. Human pilot work observed changes in oxidative-stress and senescence markers in muscle biopsies, but no measurable clinical benefit on healthspan outcomes was demonstrated Bonanni 2025. Overall, the mechanistic rationale is solid, yet human evidence remains low-tier and the score reflects that uncertainty.
VO2 Max: 5.0/10
Score: 5.0/10The evidence for SLU-PP-332 improving vo2-max scores is limited, with no human cardiopulmonary data reported in the study Billon et al. 2023. SLU-PP-332 showed enhanced treadmill endurance in mice, but the endpoint was animal running capacity, not a measured human vo2-max value. The mechanistic link relies on ERR-alpha activation, which can increase oxidative muscle metabolism, yet translation to human aerobic power remains untested. The use-case score of 5.0/10 reflects this uncertainty and the tier-2 evidence level (preclinical animal data). Responders have not yet documented changes in clinical vo2-max assessments, so the claim remains speculative.
| Use Case | Score | Summary |
|---|---|---|
| ○ Longevity / Lifespan | 4.5 | Exercise mimetics are theoretically longevity-relevant, but SLU-PP-332 has no lifespan data. Any longevity framing should be limited to pathway-level inference from ERR energy-homeostasis biology described by Giguere 2008. |
| ○ Anti-Inflammatory | 4.5 | ERR activation modulated inflammatory gene expression in preclinical kidney models. Wang et al. 2023 supports a mouse anti-inflammatory signal, but there is no human CRP, cytokine, symptom, or inflammatory-disease endpoint. |
| ○ Geriatric / Aging Population | 4.5 | An exercise mimetic could be useful for sedentary older adults if safe, but that is exactly the population where untested safety matters most. Bonanni et al. 2025 adds human myoblast pilot context, not clinical geriatric efficacy. |
| ○ Cellular Senescence | 4.0 | Bonanni et al. 2025 found favorable ex vivo marker shifts around oxidative stress, senescence, and differentiation in human myoblast work. This supports exploration, not a human senescence intervention. |
| ○ Recovery / Repair | 4.0 | Enhanced oxidative metabolism could support recovery, but no direct injury, soreness, tissue-repair, or training-recovery trial exists. Billon et al. 2023 supports endurance-like muscle programming in mice only. |
| ○ Strength / Power | 3.5 | SLU-PP-332 appears biased toward oxidative fiber and endurance programs, not hypertrophy or power. Billon et al. 2023 supports a slow-twitch-style signal, which may not improve strength or explosive performance. |
| ○ Antioxidant / Oxidative Stress | 3.5 | ERR signaling can interact with oxidative-stress biology, and Bonanni et al. 2025 found ex vivo shifts in oxidative-stress-related myoblast markers. That is not enough to call SLU-PP-332 an antioxidant in humans. |
| ○ Muscle Growth / Hypertrophy | 3.5 | The mechanism favors oxidative remodeling rather than hypertrophy. Billon et al. 2023 reported oxidative fiber changes, but no muscle-growth, lean-mass, or resistance-training endpoint exists in humans. |
| ○ Bone / Joint Health | 3.0 | Exercise benefits bone and joints through mechanical loading, but SLU-PP-332 does not replicate loading. No bone-density, cartilage, arthritis, or joint-pain data exists for the compound, so this remains mostly theoretical. |
| ○ Autophagy | 3.0 | Exercise activates autophagy, and ERR signaling overlaps with PGC-1 alpha energy programs. But SLU-PP-332 has no verified direct autophagy-marker study in humans or animals from the provided audit. |
Frequently Asked Questions
What exactly is SLU-PP-332 and how does it work mechanistically?
SLU-PP-332 is a synthetic pan-ERR agonist that activates estrogen-related receptor alpha, beta, and gamma. ERRs partner with PGC-1 alpha to regulate mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle programs. Billon et al. 2023 showed this produced an exercise-like gene-expression pattern and improved mouse endurance after injection. ERRs are distinct from classical estrogen receptors, so the compound is not simply an estrogenic drug.
Why are there no human trials yet?
No human SLU-PP-332 trial was verified in the audit. The compound remains a preclinical research tool that would need toxicology, pharmacokinetics, dose-ranging, manufacturing controls, and an Investigational New Drug pathway before legal human dosing. The audit found mouse, ex vivo, analytical, and analog studies, including Bonanni et al. 2025, but no human efficacy or safety trial, human oral dose, or human safety margin.
What did the main mouse endurance study actually show?
Billon et al. 2023 showed that sedentary male mice injected with SLU-PP-332 daily developed an exercise-like metabolic signature and improved treadmill endurance after 8 days. Muscle data showed more oxidative fiber and mitochondrial markers. That is compelling proof of concept, but it used rodent injection, not human oral dosing. Use the corrected PubMed record 36988910; the v0 record 36920450 was unrelated.
Is gray-market SLU-PP-332 safe to buy and use?
No, gray-market SLU-PP-332 is not safety-verified for human use. Even if the molecule eventually proves tolerable, vendors may sell mislabeled, impure, degraded, contaminated, or misdosed material without cGMP oversight. Analytical work like Avliyakulov et al. 2026 reflects doping-control and metabolite interest, not consumer safety validation. That work helps identify metabolites; it does not certify a bottle sold online, ever safely.
What are realistic benefits versus internet hype?
The realistic benefit is unknown in humans. The internet headline comes from mouse and animal-model data, especially Billon et al. 2023 and metabolic follow-up work from Billon et al. 2024. Human oral absorption, active dose, tissue exposure, performance effect, and long-term risk are all unvalidated. The honest expectation is possible mitochondrial signal, possible no effect, possible fatigue, and possible unexpected intolerance.
Why did Nick try it and then stop?
Nick stopped because his personal response was negative. He ran two cycles and felt progressively fatigued, drained, burnt out, and unmotivated within about two weeks, with symptoms resolving within days after stopping. That does not prove SLU-PP-332 causes fatigue in everyone; product identity, impurity, dose, and individual response could all matter. It does make the human-use uncertainty more than theoretical.
Is possession or use actually legal?
SLU-PP-332 is not FDA-approved for any indication and should not be marketed for human consumption. Vendor labels such as research use only do not create clinical validation or consumer protection. The audit found no FDA approval or named safety communication in the FDA drugs database. Personal possession is a separate legal question, but sale for human use is outside the approved-drug framework.
Who should absolutely avoid SLU-PP-332?
Avoid SLU-PP-332 if you require human safety data, take medications, have cardiovascular disease, have active or historical cancer, are under 25, are pregnant, breastfeeding, or trying to conceive, or compete in tested sport. ERRs participate in tumor-metabolism biology, with cancer-context evidence such as Ariazi et al. 2002 and Suzuki et al. 2004. Use training, sleep, nutrition, creatine, and clinician-guided metabolic care first.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| First human Phase 1 RCT releases clean 12-week safety and pharmacokinetic data | Evidence 2.0 to 3.0; Safety 4.0 to 3.0 | 5.3 / 10 👍 Worth trying |
| Phase 2 human trial confirms endurance or metabolic endpoint with clean safety monitoring | Evidence 2.0 to 3.5; Efficacy 3.5 to 4.0; Safety 4.0 to 2.5 | 6.9 / 10 💪 Strong recommend |
| Human cancer signal emerges in long-term ERR agonist users | Safety 4.0 to 5.0; Evidence 2.0 to 1.5 | 3.3 / 10 ⚠️ Caution |
| Gray-market adverse-event cluster involving hepatotoxicity or cardiac events is documented | Safety 4.0 to 5.0; Side effects 2.5 to 4.0 | 3.6 / 10 ⚠️ Caution |
| FDA warning letters or enforcement actions substantially reduce gray-market access | Legal access worsens; opportunity cost rises | 4.3 / 10 ⚖️ Neutral |
| Independent replication confirms the endurance phenotype in a second animal model | Evidence 2.0 to 2.5 | 4.7 / 10 ⚖️ Neutral |
| Clean Phase 1 plus Phase 2 plus cGMP commercial formulation with public batch testing | Evidence 2.0 to 4.0; Safety 4.0 to 2.0; Efficacy 3.5 to 4.0 | 7.6 / 10 ✅ Top-tier |
Key Evidence Sources
- Billon C et al. 2023 - Synthetic ERR alpha/beta/gamma Agonist Induces an ERR alpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity, ACS Chemical Biology. Corrected PMID for the core SLU-PP-332 mouse endurance paper; v0 PMID 36920450 was unrelated
- Billon C et al. 2023 - Synthetic ERR alpha/beta/gamma Agonist Induces an ERR alpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity, ACS Chemical Biology full text. Open full-text record for the main SLU-PP-332 endurance and oxidative-muscle proof-of-concept paper
- Billon C et al. 2023 - ACS Chemical Biology journal page for SLU-PP-332 exercise-capacity paper. Publisher DOI page confirming the intended Billon 2023 title and DOI 10.1021/acschembio.2c00720
- Billon C et al. 2024 - A Synthetic ERR Agonist Alleviates Metabolic Syndrome, Journal of Pharmacology and Experimental Therapeutics. Mouse obesity and metabolic-syndrome models; improved energy expenditure, fatty-acid oxidation, fat, glucose, and hepatic markers
- Billon C et al. 2024 - A Synthetic ERR Agonist Alleviates Metabolic Syndrome, ScienceDirect journal page. Publisher page for the JPET metabolic-syndrome paper
- Xu W et al. 2024 - Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function, Circulation. Mouse pressure-overload heart-failure model; SLU-PP-332 and SLU-PP-915 improved ejection fraction, fibrosis, and survival markers
- Wang XX et al. 2023 - Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney, American Journal of Pathology. Aged mouse kidney study; corrected bibliographic context is Am J Pathol 193(12):1969-1987
- Bonanni R et al. 2025 - Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study, Frontiers in Physiology. Human biopsy and ex vivo myoblast pilot; SLU-PP-332 shifted oxidative-stress, senescence, and differentiation markers, not clinical efficacy
- Bonanni R et al. 2025 - Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: PubMed record. PMID for the ex vivo human myoblast pilot; not a human dosing trial
- Avliyakulov NK et al. 2026 - Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERR alpha/beta/gamma Agonist for Doping-Control Purposes, Drug Testing and Analysis. In vitro human liver S9 metabolite identification for doping-control purposes; no clinical efficacy or safety
- Möller I et al. 2026 - In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential, Rapid Communications in Mass Spectrometry. Analytical characterization and metabolite work for possible performance-enhancing use detection
- Billon C et al. 2026 - An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity, Journal of Pharmacology and Experimental Therapeutics. Related oral analog evidence in mice; useful context but not direct SLU-PP-332 human evidence
- Okda HE et al. 2026 - Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling, International Journal of Biological Macromolecules. Systematic structure-activity relationship work around the SLU-PP-332 scaffold; no clinical outcomes
- Giguere V 2008 - Transcriptional Control of Energy Homeostasis by the Estrogen-Related Receptors, Endocrine Reviews. Foundational ERR energy-homeostasis review supporting the pathway context
- Audet-Walsh E, Giguere V 2015 - The multiple universes of estrogen-related receptor alpha and gamma in metabolic control and related diseases, Acta Pharmacologica Sinica. ERR alpha and gamma metabolic-control review; pathway context, not SLU-PP-332 clinical evidence
- Ariazi EA et al. 2002 - Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer, Cancer Research. Cancer-biology context for ERR signaling; not evidence that SLU-PP-332 causes cancer
- Suzuki T et al. 2004 - Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor, Cancer Research. Cancer-context ERR alpha evidence relevant to theoretical caution around chronic agonism
- Patch RJ et al. 2011 - Identification of Diaryl Ether-Based Ligands for Estrogen-Related Receptor alpha as Potential Antidiabetic Agents, Journal of Medicinal Chemistry. Early ERR alpha ligand pharmacology context; not SLU-PP-332 efficacy evidence
- Kim J et al. 2019 - Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor gamma Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer, Journal of Medicinal Chemistry. ERR gamma cancer-pharmacology context; supports caution that ERR biology is clinically complex
- WADA - What is prohibited. Authority surface used for category-level anti-doping caution; name-specific SLU-PP-332 listing was not confirmed
- FDA - Drugs@FDA database. Authority surface searched for approval status; no FDA-approved SLU-PP-332 therapeutic was verified
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Limited
Citations: Billon 2023, Billon 2024, Xu 2024, Wang 2023, Bonanni 2025, Avliyakulov 2026, Möller 2026, Okda 2026, Billon 2026
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Giguere 2008, Patch 2011, Audet-Walsh 2015, Ariazi 2002, Suzuki 2004, Kim 2019
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for SLU-PP-332
The three lenses disagree in a useful way. Modern preclinical science shows a real ERR exercise-mimetic signal in animals and cells. Historical receptor biology explains why the mechanism is coherent and why cancer and metabolic complexity matter. The traditional lens offers almost no direct support because SLU-PP-332 is synthetic and route-specific. Honest synthesis: this is a legitimate research compound, not a validated human supplement.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Lactate Baseline (pre-protocol) During | Expected Down
- hs-CRP During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
- Creatine Kinase During | Expected Watch
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Body During | Expected Up | Primary
- Drive During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Exercise Capacity Scale 1-5 | During | Expected Up
- Restlessness Scale 1-5 | During | Expected Watch
- Sleep Disruption Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe agitation or insomnia
- New muscle pain or weakness
Other interventions for Mitochondrial
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.025 − 2.665 = -0.640
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.640 / 7) × 5 = 4.5 / 10
Further learning
13 Top Peptides Companies Review & Test 2026: Where I Buy Peptides Online
After a decade in the peptide industry, I reviewed and ranked 13 reputable peptide companies across two tiers. Your source can mean the difference…
Fat Loss Peptides & Fasting: Body Recomposition Plan
Uncover the tools in Jay Campbell's new book “30 Days to Shredz.” Discover the power of intermittent fasting and performance enhancers for rapid fat…
